Phenprocoumon clinical trials
How each study uses Phenprocoumon is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 30 Dec 1957 · LIQUAMAR · NDA 011228 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2006 (1)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 5
Atrial Fibrillation Network (1) · Hoffmann-La Roche (1) · Medical University of Vienna (1) · University Medical Center Groningen (1) · Heart and Diabetes Center North-Rhine Westfalia (1) · University Hospital, Bonn (1)
Often tested with
Tested in the same studies.
Apixaban (1) · Vemurafenib (1) · Dabigatran (1) · Ticagrelor (1) · Aspirin (1) · Rivaroxaban (1) · Heparin, Low-Molecular-Weight (1)
Studies
Open first, then newest update. How each study uses Phenprocoumon is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)CompletedPhase 3Atrial Fibrillation NetworkNCT02933697Written as Phenprocoumon
- A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic MalignancyCompletedPhase 1Hoffmann-La RocheNCT01849666Written as phenprocoumon
- Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary EmbolismTerminatedPhase 3University Medical Center GroningenNCT01164046Written as vitamin K antagonists
- Antithrombotic Triple Therapy in HumansCompletedPhase 4Medical University of ViennaNCT01812200Written as Phenprocoumon, Ticagrelor, ASA
- Very Low Dose Oral Anticoagulation and Thromboembolic and Bleeding ComplicationsTerminatedPhase 4Heart and Diabetes Center North-Rhine WestfaliaNCT00528671Written as phenprocoumon
- D-Dimer Guided Oral Anticoagulant Treatment (OAT)Status unknownPhase 3University Hospital, BonnNCT00895505Written as Phenprocoumon
As the comparator · 8 — what is tested is compared with Phenprocoumon
- Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical TherapyCompletedPhase 4Charite University, Berlin, GermanyNCT03463317Written as Phenprocoumon
- Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter AblationCompletedPhase 3Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyNCT02942576Written as VKA-Based Regimen
- Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AFTerminatedPhase 2Johannes Gutenberg University MainzNCT02256683Written as Phenprocoumon
- Dabigatran as an Alternative Anticoagulant in Patients With Left Ventricular Assist Device (LVAD)TerminatedPhase 2Daniel Zimpfer, MDNCT02872649Written as Phenprocoumon
- Left Atrial Thrombus Reduction - Effect of Dabigatran Versus PhenprocoumonStatus unknownPhase 4University of UlmNCT02591225Written as Phenprocoumon
- Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial FibrillationTerminatedPhase 4Deutsches Herzzentrum MuenchenNCT01352702Written as Phenprocoumon
- Impact of Dabigatran and Phenprocoumon on ADP Induced Platelet Aggregation in Patients With Atrial FibrillationCompletedPhase 4Deutsches Herzzentrum MuenchenNCT01339819Written as Phenprocoumon
- Study to Find Out the Appropriate Initial Dose of the Anticoagulant Drug PhenprocoumonCompletedPhase 4Cantonal Hospital of St. GallenNCT00586287Written as Phenprocoumon
Codes
What other systems call Phenprocoumon · ClinicalTrials.gg INT007997
- MeSH (NLM) D010644PhenprocoumonConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) Q08SIO485DPHENPROCOUMONConfirmed FDA, NLM, Wikidata
- RxNorm 8150Confirmed FDA, Wikidata
- Wikidata Q267896phenprocoumonConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66374PhenprocoumonOne source FDA
- DrugBank DB00946One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D010644 | Phenprocoumon | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | Q08SIO485D | PHENPROCOUMON | Confirmed FDA, NLM, Wikidata |
| RxNorm | 8150 | — | Confirmed FDA, Wikidata |
| Wikidata | Q267896 | phenprocoumon | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66374 | Phenprocoumon | One source FDA |
| DrugBank | DB00946 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.